Certolizumab pegol (Cimzia)
Certolizumab pegol is a biologic medication for the treatment of Crohn's disease, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
It is a fragment of a monoclonal antibody specific to TNF-alpha to neutralise it.
It is administered through subcutaneous injection every month.
In 2016, it sold €120 million in Europe.
It has an immunogenicity rate of 3-37%.
Labs that test for drug level:
Labs that test for ADA titre: